NCT # 02954874 S1418/BR006 A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1cm Residual Invasive Cance

    Research project

    StatusActive
    Effective start/end date4/30/174/29/18

    Funding

    • NRG Oncology